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Working Group Technology Assessment for Health Care.
The German Cervical Cancer Model Group, an interna-
tional and interdisciplinary network, was established to
1) assess German clinical practice patterns; 2) create a
database of German epidemiological, clinical, and eco-
nomic model parameters; 3) develop a German decision
model based on previously published and validated 
international models, and 4) perform cost-effectiveness
analyses. RESULTS: Based on international studies, 
the discounted incremental cost-effectiveness ratios
(ICER) compared to conventional smears were
US$10,000–37,000 per life year saved (LYS) for liquid
based testing, 22,000–29,000 US$/LYS for automated
primary screening, and 16,000–48,000 US$/LYS for 
automated re-screening technologies, assuming a 3-year
screening interval, but was much less attractive for more
frequent screening intervals. In comparison, for the
German health care context screening with a combina-
tion of liquid-based preparation plus computer-assisted
smear-analyses compared to conventional smears resulted
in 31,000 €/LYS for a 3-year screening interval, 56,000
€/LYS for a 2 year screening interval, and 300,000 
€/LYS for annual screening. Results were most sensitive
to assumptions about the costs and performance of
screening tests and population compliance. CONCLU-
SIONS: Technologies improving performance of cervical
cancer screening are reasonably cost-effective at screen-
ing intervals of three years and greater. Based on the
current clinical standard of annual cervical cancer screen-
ing in Germany, the introduction of new screening 
technologies would likely not be cost-effective without 
a reduction in screening frequency.
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OBJECTIVES: A single 6mg once-per-cycle injection of
pegﬁlgrastim was compared with daily ﬁlgrastim (mean
10.5 days/cycle) in a double-blind, randomized, multina-
tional, phase 3 study in patients (pts) receiving 4 cycles
of myelosuppressive chemotherapy. The observed inci-
dences of febrile neutropenia (13% v 20%), hospitaliza-
tion (18% v 31%), and IV anti-infective use (17% v 21%)
were lower across all cycles in the pegﬁlgrastim arm. 
Pegﬁlgrastim was safe and well tolerated. This economic
analysis was conducted to determine if pegﬁlgrastim
would lead to a reduction in resource utilization and cost.
METHODS: Duration of all-cause hospitalization, IV
anti-infective use, and transfusion in each cycle and across
all cycles were compared. Unit costs were available for
ﬁve participating countries: Germany, Italy, the Nether-
lands, Spain, and the US. Each set of country speciﬁc unit
costs was applied to the entire study sample, and the total
cost was calculated as the sum of costs of hospitalization,
IV anti-infectives, and transfusion. All costs were con-
verted into year 2000 Euros. RESULTS: Economic analy-
sis was performed on 152 pts (77 in pegﬁlgrastim arm)
evaluable for efﬁcacy (97% of all randomized pts). The
mean [sd] durations of all cause hospitalizations (1.18
[3.10] v 3.77 [8.72] days) and IV anti-infective use (0.70
[2.34] v 2.32 [6.09] days) were signiﬁcantly lower 
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(p < 0.05) in the pegﬁlgrastim arm. The total cost across
all cycles in the pegﬁlgrastim arm was signiﬁcantly lower
regardless of what country costs were used (p < 0.02 in
all comparisons). The mean difference in Euros was 672
(Italian), 759 (Spanish), 982 (Dutch), 1068 (German),
and 1836 (US). CONCLUSIONS: Compared with daily
ﬁlgrastim, once-per-cycle ﬁxed-dose pegﬁlgrastim led to
reduced length of hospitalization and IV anti-infective
use, and total cost post chemotherapy. In addition to its
simplicity and convenience, pegﬁlgrastim appears to have
superior economic value to daily ﬁlgrastim.
PCN5
COMPARING THE COST-EFFECTIVENESS OF
FRONT-LOADED DARBEPOETIN ALFA WITH
EPOETIN ALFA FOR ANEMIA MANAGEMENT IN
CHEMOTHERAPY-TREATED CANCER PATIENTS
IN UNITED STATES
Glaspy J1,Tchekmedyian N2, Gupta S3
1University of California-Los Angeles, Los Angeles, CA, USA;
2Paciﬁc Shores Medical Group, Long Beach, CA, USA;
3Amgen,Thousand Oaks, CA, USA
OBJECTIVES: A recent 12-week randomized clinical trial
evaluated the dose and schedule of “front loading”/main-
tenance phase darbepoetin alfa required to optimize the
hemoglobin (hgb) response rates (hgb increase ≥2g/dL in
absence of RBC transfusion) among solid tumor patients
with chemotherapy-induced anemia. A randomized group
of epoetin alfa patients (40,000U/wk; 37% patients dose
escalated to 60,000U/wk at 6 weeks for inadequate
response) served as the control. Recent literature indicates
the mean duration of treatment with epoetin alfa for
chemotherapy-induced anemia to be 16 to 24 weeks. 
We designed a 20-week model to evaluate the cost-
effectiveness of the optimal dose and schedule of 
“front loading”/maintenance phase darbepoetin alfa (4.5
mcg/kg/wk for 4 weeks followed by 3mcg/kg/Q2W; 
n = 30) compared to epoetin alfa (n = 30). METHODS:
Average wholesale prices of the two drugs in United States
were used as the sole cost driver over the modeled 20-
week anemia treatment period. For the cost-effectiveness
analyses, 2 efﬁcacy measures (% patients with hgb
response and mean increase in hgb from baseline at the
end of week 12) were used. RESULTS: Mean cumulative
20-week doses per patient for darbepoetin alfa and
epoetin alfa were estimated to be 2,940mcg and 903,600
U, respectively. Darbepoetin alfa provided multiple 
efﬁcacy advantages over epoetin alfa: >32% patients with
hgb response [65% (47,84) versus 49% (29,69)], >27%
higher mean rise in hgb (1.31 versus 1.03), faster median
time to response (day 50 versus day 78) and greater
reduction in fatigue (6.0 versus ¨C1.1). Despite a >20%
cost increment, cost-effectiveness ratios (cost per %
patients with hgb response and cost per rise in hgb from
baseline) were superior for darbepoetin alfa ($22,570
versus $24,637 and $11,199 versus 11,720, respectively).
CONCLUSIONS: Compared to epoetin alfa therapy,
front-loaded darbepoetin alfa provides superior beneﬁts
to cancer patients with chemotherapy-induced anemia
and is cost-effective.
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According to two multicenter, comparative, randomized,
opened-labeled studies efﬁcacy of raltitrexed and 5-
ﬂuorouracil plus leucovorin (5-FU + LV) for advanced
colorectal cancer doesn’t differ signiﬁcantly. 5-FU + LV in
Russia is much cheaper in Russia than raltitrexed but
there is a signiﬁcantly higher rate of severe side effects,
such as neutropenia and mucositis, that may have 
inﬂuenced the costs. OBJECTIVE: Economical evaluation 
of raltitrexed versus 5-FU + LV (regimen Machover) for
treatment of advanced colorectal cancer in Russia.
METHODS: Decision model was used to quantify costs
of alternative treatment. Published results from two trials
were used to estimate probabilities of end-points 
(neutropenia, mucositis or no severe side-effects). Medical
costs of treatment included costs of chemotherapy, 
treatment for side effects (neutropenia and mucositis),
hospitalization and/or visits. Costs for chemotherapy
were calculated on the basis of standard recommenda-
tions; costs for neutropenia and mucositis were assessed
by retrospective analysis of 60 medical charts at Moscow
Hematological Center. One-way sensitivity analysis was
performed. RESULTS: The medium costs on one cycle of
cytostatic therapy were 20 771,00 rubles (716,2 USD) for
raltitrexed and 7 407,55 rubles (255,4 USD) for 5-FU +
LV. The median treatment cost for side effects has com-
pounded 25 373,95 rubles (875,0 USD) per person with
neutropenia and 52 050,85 rubles (1794,9 USD) per
person with mucositis. Expected costs for treatment of
colorectal cancer taking into account both side effects was
85 647,46 rubles (2953,4 USD) for raltitrexed and 67
656,95 rubles (2333,0 USD) for 5-FU + LV. Sensitivity
analysis demonstrated that the expected costs of
raltitrexed therapy are less than 5-FU + LV when
maximum value of costs for side effects are included into
the model. CONCLUSION: Raltitrexed is more safe but
more expensive than 5-FU + LV, but difference in costs
decreases when severe side effects are taken into account.
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